Rhumbline Advisers decreased its holdings in shares of ChemoCentryx, Inc. (NASDAQ:CCXI) by 10.9% in the 1st quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The institutional investor owned 59,407 shares of the biopharmaceutical company’s stock after selling 7,231 shares during the quarter. Rhumbline Advisers owned 0.09% of ChemoCentryx worth $3,044,000 at the end of the most recent quarter.
Other hedge funds and other institutional investors have also modified their holdings of the company. Teachers Retirement System of The State of Kentucky grew its holdings in shares of ChemoCentryx by 7.0% during the fourth quarter. Teachers Retirement System of The State of Kentucky now owns 83,425 shares of the biopharmaceutical company’s stock worth $5,166,000 after purchasing an additional 5,445 shares in the last quarter. UBS Asset Management Americas Inc. grew its holdings in shares of ChemoCentryx by 21.3% during the fourth quarter. UBS Asset Management Americas Inc. now owns 58,246 shares of the biopharmaceutical company’s stock worth $3,607,000 after purchasing an additional 10,224 shares in the last quarter. Artal Group S.A. purchased a new stake in ChemoCentryx in the fourth quarter worth approximately $40,248,000. Teacher Retirement System of Texas purchased a new stake in ChemoCentryx in the fourth quarter worth approximately $272,000. Finally, First Trust Advisors LP boosted its stake in ChemoCentryx by 117.0% in the fourth quarter. First Trust Advisors LP now owns 51,373 shares of the biopharmaceutical company’s stock worth $3,181,000 after buying an additional 27,696 shares in the last quarter. 78.76% of the stock is owned by institutional investors.
Shares of ChemoCentryx stock opened at $11.54 on Friday. The company has a debt-to-equity ratio of 0.04, a quick ratio of 7.14 and a current ratio of 7.14. The company has a market capitalization of $804.92 million, a P/E ratio of -12.54 and a beta of 1.45. The company’s 50 day simple moving average is $27.59. ChemoCentryx, Inc. has a 52 week low of $9.53 and a 52 week high of $70.29.
CCXI has been the subject of several research reports. Raymond James reaffirmed an “outperform” rating and issued a $51.00 target price (down previously from $120.00) on shares of ChemoCentryx in a research note on Thursday, May 13th. SVB Leerink reaffirmed a “market perform” rating and issued a $17.00 target price (down previously from $84.00) on shares of ChemoCentryx in a research note on Thursday, May 13th. JPMorgan Chase & Co. reissued an “underweight” rating and set a $17.00 price objective (down previously from $57.00) on shares of ChemoCentryx in a research note on Thursday, May 13th. TheStreet lowered ChemoCentryx from a “c-” rating to a “d” rating in a research note on Tuesday, March 2nd. Finally, HC Wainwright dropped their price objective on ChemoCentryx from $101.00 to $28.00 and set a “buy” rating for the company in a research note on Friday, May 7th. One research analyst has rated the stock with a sell rating, four have given a hold rating and five have assigned a buy rating to the stock. ChemoCentryx presently has a consensus rating of “Hold” and a consensus price target of $38.00.
In other news, COO Tausif Butt acquired 10,870 shares of the firm’s stock in a transaction on Friday, May 7th. The stock was acquired at an average price of $11.06 per share, for a total transaction of $120,222.20. Following the completion of the acquisition, the chief operating officer now owns 10,870 shares in the company, valued at $120,222.20. The transaction was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through the SEC website. 8.00% of the stock is currently owned by corporate insiders.
ChemoCentryx Company Profile
ChemoCentryx, Inc, a clinical-stage biopharmaceutical company, focuses on the development and commercialization of new medications for inflammatory disorders, autoimmune diseases, and cancer in the United States. It develops Avacopan, an orally administered selective complement 5a receptor inhibitor for the treatment of anti-neutrophil cytoplasmic autoantibody-associated vasculitis; and completed Phase II clinical trial for the treatment of patients with severe hidradenitis suppurativa, as well as patients with complement 3 glomerulopathy.
Read More: Balance Sheet
Receive News & Ratings for ChemoCentryx Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for ChemoCentryx and related companies with MarketBeat.com's FREE daily email newsletter.